Skip To Content

Sharing perspectives leads to greater understanding and fuels innovation.

The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.

February 27, 2020 · Clinical Connection team
Voltaren Gel 1% (diclofenac sodium topical gel) ― a common medication in workers’ compensation and auto no-fault ― will soon transition from prescription (Rx) to over-the-counter (OTC) status, according to the U.S. Food and Drug Administration (FDA). Read more...
February 23, 2020 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
February 13, 2020 · Lavonya Chapman Esq RN CMSP
An unpublished version of the long-waited Section 111 mandatory insurer reporting (MIR) Civil Money Penalties (CMP) has been released and is expected to be published in the Federal Register on 02/18/2020. Read more...
February 03, 2020 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
January 28, 2020 · Rafael Gonzalez
Although we certainly hear a great deal about Medicare becoming increasingly more aggressive with primary payers (responsible employers, corporations, insurers, self-insured entities and third-party administrators), the federal government is also becoming just as unforgiving with beneficiaries’ attorneys. Read more...
January 16, 2020
The U.S. Food and Drug Administration (FDA) has approved a new medication to treat acute (immediate) migraine with or without aura (often described as a visual disturbance such as flashing lights) in adults. Read more...
December 19, 2019
On October 10, 2019, the United States Court of Appeals for the Ninth Circuit published its opinion on California Insurance Guarantee Association v. Azar, concluding that CIGA is not a primary plan under the Medicare secondary payer provisions, but an insurer of last resort, therefore, is under no obligation to reimburse CMS for conditional payments made on behalf of workers’ compensation insureds. Read more...
December 17, 2019 · Clinical Connection team
On December 19, 2019, the U.S. Food and Drug Administration (FDA) issued a warning that patients with certain respiratory risk factors who are using gabapentin (Neurontin®, Gralise®, Horizant®) or pregabalin (Lyrica®, Lyrica® CR) may experience serious breathing difficulties. Read more...
     Next >>
Page 1 of 7

Subscribe today to receive our latest blogs, articles and more.